Changes in type VI collagen degradation reflect clinical response to treatment in rheumatoid arthritis patients treated with tocilizumab
Authors' conclusion
These findings suggest that quantifying type VI collagen turnover may aid in identifying patients less likely to respond to treatment, indicating a new path towards optimizing patient care.
Study context
- Population
- Rheumatoid arthritis (RA) patients treated with anti-IL-6R treatment (tocilizumab)
- Comparison
- Tocilizumab 4 mg and 8 mg vs placebo
- Outcome
- Relationship between Col VI degradation (serum C6M) and clinical response to anti-IL-6R treatment
Methodological detailsplacebo-controlled, linear mixed models, logistic regression
- Placebo-controlled
- Linear mixed models
- Logistic regression
Main finding
As reported in the abstract
Serum C6M concentrations
- Both 4 mg and 8 mg Tocilizumab (TCZ) reduced serum C6M concentrations vs placebo
- C6M levels more reduced in responders vs early non-responders
- Lower early reduction in C6M associated with reduced odds of ACR treatment response and lowered disease activity
Original publication
Changes in type VI collagen degradation reflect clinical response to treatment in rheumatoid arthritis patients treated with tocilizumab. Arthritis Res Ther. Published 2 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →